Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

4.690 -0.130 (-2.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 131 in relapsed/refractory Waldenstrom's macroglobulinemia showed an 80%... 
Via Benzinga
CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024
CLRB stock results show that Cellectar Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains. 
Via InvestorPlace
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private. 
Via InvestorPlace
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
CLRB stock results show that Cellectar Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Preview For Cellectar Biosciences
 
Via Benzinga
Recap: Cellectar Biosciences Q1 Earnings
 
Via Benzinga
Recap: Cellectar Biosciences Q3 Earnings
Cellectar Biosciences (NASDAQ:CLRB) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Cellectar Biosciences: Q2 Earnings Insights
Cellectar Biosciences (NASDAQ:CLRB) reported its Q2 earnings results on Friday, August 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why
Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, achieving 64% complete remission and 73% overall response rate. Roth Capital... 
Via Benzinga
Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?
Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory... 
Via Benzinga
Wells Fargo Is Warming Up to Enphase Energy (ENPH) Stock
Enphase Energy stock is rising higher on Monday as investors react to a new upgrade and increased price target for ENPH from Wells Fargo. 
Via InvestorPlace
Why Is Spirit AeroSystems (SPR) Stock Down 14% Today?
Spirit AeroSystems stock is falling hard on Monday as investors in SPR react to one of the company's flights experiencing a mid-air blowout. 
Via InvestorPlace
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday! 
Via InvestorPlace
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Cellectar Biosciences stock is up on Monday as investors celebrate positive study results with heavy trading of CLRB stock this morning. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Crude Oil Rises 1%; Verb Technology Shares Spike Higher
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling 100 points on Tuesday. The Dow traded down 0.31% to 34,728.66 while the NASDAQ rose 0.11% to 14,047.61. The S&P... 
Via Benzinga
Topics Stocks
Nasdaq Turns Higher; US Factory Orders Fall 2.1% In July
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.15% to 34,785.92 while the NASDAQ rose 0.12% to 14,048.20. The S&P 500, also... 
Via Benzinga
Topics Stocks
Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Verb Technology Company, Inc. (NASDAQ: VERB) shares jumped 164% to $1.89 after the completed and launched a technology integration and strategic relationship with global social media platform... 
Via Benzinga
Cellectar Biosciences Inc. (NASDAQ: CLRB) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Why Zoom Video Is Trading Lower By 11%; Here Are 28 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 58.2% to $0.3070 in pre-market trading. Quotient recently reported a wider Q1 loss. 
Via Benzinga
Why Is Infrastructure and Energy Alternatives Higher By Around 29%? 37 Stocks Moving In Monday's Mid-Day Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis. 
Via Benzinga
Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday. 
Via Benzinga
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback